TCR γ/δ + separation from TCR α/β + with a column-free immuno-magnetic workflow

INTRODUCTION

In recent years T cell receptor (TCR) cell therapy has gained popularity due to a range of possible treatments for cancer and some infectious diseases it could provide. Since $\gamma\delta$ T-cells constitute promising effector cell compartments for cancer immunotherapy, novel $\gamma\delta$ T-cell-based immunotherapies are being developed. Although advancements in TCR engineering, manufacturing, and clinical applications have led to significant progress in the field, challenges in optimizing the TCR cell therapy development, efficacy, and safety remain. The MARS[®] platform provides an easy method to optimize and scale up $\gamma\delta$ T-cells providing specialists with a new tool to help maximize the clinical potential of TCR therapies.









Using MARS[®] Bar platform ensures:

- ${\ensuremath{\boxtimes}}$ Over 98% purity and very high recovery of $\gamma\delta$ T-cells
- ☑ Easily re-run the sample to improve purity
- ☑ Fast and Simple workflow (up to 6mL / min)
- ✓ No magnetic column costs
- ☑ Intuitive, touchscreen interface
- ☑ Low consumables **cost**, low reagent **consumption**

MARS[®] Bar family offers both, a small-scale system (Flex) for easy assay optimization of up to 3 samples in parallel, and a fully enclosed bag-in-bag-out (BIBO) configuration for highperformance, sterile cell processing and subsequent culturing.

For research use only. Not for use in therapeutic or diagnostic procedures.

© Copyright 2023. All rights reserved. Applied Cells and MARS[®] are registered trademarks of Applied Cells, Inc. All other trademarks are the property of their respective owners.



3350 Scott Blvd Bldg 6 Santa Clara, CA 95054 +1 800-960-3004

AC_A024A